PharmaTimes

PharmaTimes presents a distinctive mix of news articles, interviews, features, case studies, analyses, and opinions on the pressing matters in the pharmaceutical and healthcare industries. With a broad editorial approach and a commitment to delivering insightful and engaging content from the viewpoints of industry professionals, payers, and patients, PharmaTimes fosters important discussions for our audience of key decision-makers in pharma and healthcare. Our PharmaTimes Competitions play a vital role in our organization, offering a special platform for the industry to highlight its most skilled individuals in marketing, communications, sales, and clinical research. These competitions are unlike any other, as they allow participants to engage in real-world challenges created by independent experts in the field. Contestants can assess their abilities against their peers and receive constructive feedback, making the entire experience a valuable opportunity for growth and learning.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#1131372

United Kingdom

#195148

Health/Biotechnology and Pharmaceuticals

#93

Traffic sources

Monthly visitors

Articles

NICE recommends sparsentan for IgA nephropathy

1 week ago | pharmatimes.com | John Pinching

The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in England as a treatment for primary IgA nephropathy. The decision follows UK regulatory approval and is based on results from the phase 3 PROTECT trial. NICE’s guidance states that sparsentan can be prescribed to adults with a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio of 0.75 g/g or more.
Oxford Brain Diagnostics to launch groundbreaking dementia diagnosis technology

1 week ago | pharmatimes.com | John Pinching

With over 55 million people worldwide living with dementia, Oxford Brain Diagnostics (OBD) is set to revolutionise early diagnosis with its patented Cortical Disarray Measurement (CDM®) technology. The software analyses standard MRI scans to provide an objective measure of neurodegeneration, offering a more precise way to assess brain health. Following FDA 510(k) clearance and UKCA self-certification, OBD will now roll out its technology commercially across healthcare sectors in the UK and US.
MHRA Board meets in Scotland for first time, reinforcing UK-wide health priorities

2 weeks ago | pharmatimes.com | John Pinching

The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time, marking a significant step in the agency’s approach to delivering health and innovation priorities across the UK.
Sonrai and AOA Dx partner to accelerate ovarian cancer test development

2 weeks ago | pharmatimes.com | John Pinching

Sonrai Analytics and AOA Dx have announced a partnership to accelerate the development of AOA’s multi-omic liquid biopsy test for ovarian cancer. The collaboration will use Sonrai’s AI-powered platform to validate diagnostic biomarkers, improving accuracy and clinical utility. AOA will integrate Sonrai’s cloud-based analytics platform to analyse multi-modal data, including multi-omic and clinical information.
Bee Koen Low - PharmaTimes

2 weeks ago | pharmatimes.com | Emily Kimber

Kelso Pharma has announced the appointment of Bee Koen Low as its first Chief Operating Officer. Low brings more than 20 years of pharmaceutical industry experience to the role, which she takes on after most recently serving as Director of Operations Diligence and Integration at Advanz Pharma. Low held a number of other leadership positions over more than a decade at Advanz, focusing on project management, technical operations, and operations diligence and integration.
Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia

2 weeks ago | pharmatimes.com | Emily Kimber

Ionis Pharmaceuticals has shared positive top-line results from a late-stage study of olezarsen in hypertriglyceridaemia. The phase 3 Essence trial, conducted with Ionis’ research partner the TIMI Study Group, has been evaluating the RNA-targeted drug in adults aged 18 years and older with moderate hypertriglyceridaemia.
Elizabeth Rebeil

2 weeks ago | pharmatimes.com | Emily Kimber

Veranova has announced the appointment of Elizabeth Rebeil as its new Global Vice President of Supply Chain and Operational Excellence. Rebeil brings extensive experience in supply chain management to the role, which she takes on after most recently serving as Vice President of Supply Chain, Procurement and Customer Service at QuVa Pharma.
FDA approves Amneal’s self-administered migraine drug Brekiya

2 weeks ago | pharmatimes.com | Emily Kimber

The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ Brekiya (dihydroergotamine mesylate) injection to treat acute migraine and cluster headaches in adults. The therapy, which is expected to be available for eligible patients in the second half of 2025, is now the first dihydroergotamine (DHE) auto-injector to be approved by the regulator. Headache disorders are among the most common disorders of the nervous system, according to the World Health Organization.
MHRA approves guselkumab for Crohn’s disease and ulcerative colitis

2 weeks ago | pharmatimes.com | John Pinching

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s disease and ulcerative colitis (UC). Already used for plaque psoriasis and psoriatic arthritis, guselkumab has shown efficacy in adults with moderately to severely active Crohn’s disease and UC who have not responded to other treatments or experienced unacceptable side effects.
Massalia Therapeutics launches to advance novel treatments for complex conditions

2 weeks ago | pharmatimes.com | John Pinching

Massalia Therapeutics, a biotechnology spin-off from the C2VN Institute, has officially launched with a mission to develop innovative treatments for patients with fibrotic, neoplastic and neovascularized conditions. The company’s sole-in-class therapeutic platform bridges the intersection of these diseases, offering a new approach to tackling their complex interactions.